<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076682</url>
  </required_header>
  <id_info>
    <org_study_id>2107239-9</org_study_id>
    <nct_id>NCT05076682</nct_id>
  </id_info>
  <brief_title>Reverse Triple Negative Immune Resistant Breast Cancer</brief_title>
  <acronym>Renaissance</acronym>
  <official_title>Reverse Triple Negative Immune Resistant Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, open-label, three-arm parallel study evaluating the efficacy and safety&#xD;
      of combined treatment (sodium cromoglicate, choline, or efavirenz) with immune checkpoint&#xD;
      inhibitor in mTNBC (triple negative breast cancer) patients who progressed during previous&#xD;
      immune checkpoint inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, open-label, three-arm parallel study evaluating the efficacy and safety&#xD;
      of combined treatment (sodium cromoglicate, choline, or efavirenz) with immune checkpoint&#xD;
      inhibitors in metastatic TNBC (triple negative breast cancer) patients who progressed during&#xD;
      or following previous immune checkpoint inhibitors. The investigators have achieved a&#xD;
      breakthrough in the FUTURE study with an ORR (objective response rate) reaching 52.6% in IM&#xD;
      (immunomodulatory) subtype TNBC patients. Despite this, there are still some IM subtype&#xD;
      patients resistant to immunotherapy. How to reverse immunotherapy resistance or how to&#xD;
      increase the sensitivity of immunotherapy efficacy, has become an urgent clinical problem to&#xD;
      be solved. The preclinical results of our center show that TMAO, choline, and efavirenz play&#xD;
      a potentially important role in regulating the tumor immune microenvironment. Oral choline&#xD;
      can improve TMAO content in mouse serum, play the role of activating anti-tumor immunity, and&#xD;
      improve immunotherapy efficacy. Preclinical studies of our center also show that sodium&#xD;
      cromoglicate can enhance the anti-tumor immune response by inhibiting the activation of mast&#xD;
      cells, increase the infiltration and function of cytotoxic CD8+ T cells, inhibit the growth&#xD;
      of tumors in mice, and enhance the efficacy of PD-1 inhibitors in mice. Furthermore, another&#xD;
      preclinical study of our center shows that efavirenz can enhance the anti-tumor immune&#xD;
      response by inhibiting the retrotransposon of LINE-1 and decreasing intratumor heterogeneity.&#xD;
      The combination of efavirenz and PD-1 inhibitors effectively inhibits tumor growth in mice.&#xD;
      Based on preclinical studies, the investigators designed this study to enroll mTNBC patients&#xD;
      who have progressed during or following immunotherapy, and to explore the efficacy of sodium&#xD;
      cromoglicate, choline, or efavirenz combined with immunotherapy at a clinical level,&#xD;
      providing new strategies of combined treatment for TNBC patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2022</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Baseline until disease progression or loss of clinical benefit, assessed up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune changes in peripheral blood</measure>
    <time_frame>Baseline until disease progression or loss of clinical benefit, assessed up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Baseline through end of study, assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Randomization to death from any cause, through the end of study,assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and treatment-related AEs</measure>
    <time_frame>Randomization to death from any cause, through the end of study,assessed up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis1</measure>
    <time_frame>Baseline until disease progression or loss of clinical benefit, assessed up to 6 months</time_frame>
    <description>Mast cell function will be measured in pretreatment tissues to predict therapy response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis2</measure>
    <time_frame>Baseline until disease progression or loss of clinical benefit, assessed up to 6 months</time_frame>
    <description>The expression of ZNF689 will be measured in pretreatment tissues to predict therapy response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis3</measure>
    <time_frame>Baseline until disease progression or loss of clinical benefit, assessed up to 6 months</time_frame>
    <description>Before and after treatment, DNA and RNA were extracted from the tissues to detect the copy number and mRNA expression of long interspersed element-1 (LINE-1).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Choline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Choline with anti-PD-1 immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium cromoglicate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium cromoglicate with anti-PD-1 immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efavirenz with anti-PD-1 immunotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choline</intervention_name>
    <description>Choline 300mg tid or 500mg bid, p.o</description>
    <arm_group_label>Choline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-PD-1 antibody and chemotherapy</intervention_name>
    <description>PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)</description>
    <arm_group_label>Choline</arm_group_label>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_label>Sodium cromoglicate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Cromoglicate</intervention_name>
    <description>Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)</description>
    <arm_group_label>Sodium cromoglicate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Efavirenz 600mg qd, p.o</description>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG Performance Status of 0, 1, or 2&#xD;
&#xD;
          -  Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER,&#xD;
             and PR expression)&#xD;
&#xD;
          -  Radiologic/objective evidence of recurrence or disease progression after&#xD;
             immunotherapy(combined with targeted therapy or chemo ) for metastatic breast&#xD;
             cancer(MBC)&#xD;
&#xD;
          -  Adequate hematologic and end-organ function, laboratory test results, obtained within&#xD;
             14 days prior to initiation of study treatment.&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive measures as outlined for each specific&#xD;
             treatment arm&#xD;
&#xD;
          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1&#xD;
             (RECIST v1.1)&#xD;
&#xD;
          -  have the cognitive ability to understand the protocol and be willing to participate&#xD;
             and to be followed up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing CNS metastases&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  History of malignancy other than breast cancer within 5 years prior to screening, with&#xD;
             the exception of those with a negligible risk of metastasis or death&#xD;
&#xD;
          -  Treatment with chemotherapy, radiotherapy,immunotherapy or surgery (outpatient clinic&#xD;
             surgery excluded) within 3 weeks prior to initiation of study treatment.&#xD;
&#xD;
          -  Pregnancy or breastfeeding, or intention of becoming pregnant during the study&#xD;
&#xD;
          -  History of allergies to the drug components of this trial&#xD;
&#xD;
          -  History of eosinophilosis or mastocytosis&#xD;
&#xD;
          -  Patients who have been using oral steroid hormones for a long time will need to stop&#xD;
             for 4 weeks if they have used them occasionally in the past&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhimin Shao, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan U</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhimin Shao, Professor</last_name>
    <phone>08664175590</phone>
    <phone_ext>88807</phone_ext>
    <email>zhimingshao@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhonghua Wang, Professor</last_name>
    <phone>08664175590</phone>
    <phone_ext>88807</phone_ext>
    <email>zhonghuawang95@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhonghua Wang, Professor</last_name>
      <phone>+8664175590</phone>
      <phone_ext>88807</phone_ext>
      <email>zhonghuawang95@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yin Liu, Doctor</last_name>
      <phone>+8664175590</phone>
      <phone_ext>88603</phone_ext>
      <email>liuyinfudan@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>September 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>September 29, 2022</last_update_submitted>
  <last_update_submitted_qc>September 29, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>TNBC</keyword>
  <keyword>molecular subtype</keyword>
  <keyword>precision Treatment</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>choline</keyword>
  <keyword>sodium cromoglicate</keyword>
  <keyword>efavirenz</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Cromolyn Sodium</mesh_term>
    <mesh_term>Choline</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

